| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | Nutlin-3 | CTRPv2 | pan-cancer | AAC | 0.085 | 0.02 |
| mRNA | AZD6244 | CCLE | pan-cancer | AAC | 0.11 | 0.02 |
| mRNA | MS-275 | CTRPv2 | pan-cancer | AAC | 0.079 | 0.02 |
| mRNA | sirolimus:bortezomib (250:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.081 | 0.02 |
| mRNA | AT13387 | CTRPv2 | pan-cancer | AAC | 0.11 | 0.02 |
| mRNA | AT-7519 | GDSC1000 | pan-cancer | AAC | 0.07 | 0.02 |
| mRNA | BRD-K11533227 | CTRPv2 | pan-cancer | AAC | 0.089 | 0.02 |
| mRNA | salermide | CTRPv2 | pan-cancer | AAC | 0.11 | 0.02 |
| mRNA | Gemcitabine | CTRPv2 | pan-cancer | AAC | 0.076 | 0.02 |
| mRNA | Bleomycin | CTRPv2 | pan-cancer | AAC | 0.086 | 0.02 |